Want to see KR:009420 full AI Analyst Report?
Hanall Biopharma Co., Ltd. (009420) Financial Statements
Hanall Biopharma Co., Ltd. Financial Overview
Hanall Biopharma Co., Ltd.'s market cap is currently $1.90T. The company's EPS TTM is $-482.08; its P/E ratio is -87.32; Hanall Biopharma Co., Ltd. has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 155.18B | $ 138.94B | $ 134.91B | $ 110.00B | $ 101.59B |
| Gross Profit | $ 79.10B | $ 73.31B | $ 75.04B | $ 61.97B | $ 60.33B |
| Operating Income | $ -1.61B | $ 230.47M | $ 3.06B | $ 1.51B | $ 10.10B |
| EBITDA | $ 1.94B | $ 3.35B | $ 6.58B | $ 5.05B | $ 11.45B |
| Net Income | $ -5.56B | $ -1.80B | $ 3.51B | $ 251.47M | $ 8.90B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 24.74B | $ 24.71B | $ 56.50B | $ 53.93B | $ 80.57B |
| Total Assets | $ 225.22B | $ 212.88B | $ 239.75B | $ 213.45B | $ 198.48B |
| Total Debt | $ 31.92B | $ 1.45B | $ 1.29B | $ 1.31B | $ 1.34B |
| Net Debt | $ 7.17B | $ -14.94B | $ -32.43B | $ -15.53B | $ -11.46B |
| Total Liabilities | $ 63.54B | $ 44.53B | $ 53.53B | $ 45.19B | $ 34.99B |
| Stockholders' Equity | $ 161.68B | $ 168.35B | $ 186.22B | $ 168.26B | $ 163.49B |
| Cash Flow | |||||
| Free Cash Flow | $ -3.29B | $ -13.71B | $ 20.45B | $ 17.53B | $ -8.16B |
| Operating Cash Flow | $ -2.34B | $ 9.36B | $ 29.64B | $ 25.20B | $ 839.87M |
| Investing Cash Flow | $ -18.83B | $ -27.49B | $ -11.89B | $ -10.59B | $ 8.03B |
| Financing Cash Flow | $ 29.57B | $ 759.59M | $ -813.51M | $ -10.64B | $ -306.53M |
Currency in KRW